



STAR PHARMACEUTICAL LIMITED
(Company Registration No. 200500429W)
(Incorporated in Singapore)

PURCHASE OF OFFICE PREMISE

1. Introduction

The Board of Directors (the “**Board**”) of STAR Pharmaceutical Limited (the “**Company**”, and together with its subsidiaries, collectively the “**Group**”) is pleased to announce that the Company had obtained an Option to Purchase (“**Option**”) for the purchase of office premise Unit No. #16 - 21 of Vision Exchange at 2 Venture Drive, Singapore 608526 (the “**Property**”) (the “**Acquisition**”).

2. Information on The Property

Vision Exchange is a 99-year leasehold property being developed by Sim Lian JV (Vision) Pte Ltd. The total floor area for the Property is 840 square feet.

3. Rationale for the Acquisition

The Group intends to utilise the Property for its own use upon completion of the development of Vision Exchange. The Board believes that the new office premise will provide ample space for the present and future needs of the Group, as well as rendering a conducive working environment for its staff in Singapore. However, in the interim period, the Company may consider leasing out the Property to tenants which will generate rental income for the Group.

4. Purchase Price and source of funds

The total purchase price is S\$ 2,111,110, which will be funded by internal resources and bank borrowings.

5. Financial effect

The Acquisition is not expected to have any material financial impact on the consolidated net tangible asset and earnings per share of the Company for the financial year ending 31 December 2015.

6. Relative figures computed on the bases set out in Rule 1006 of the Singapore Exchange Trading Limited (“SGX-ST”)

The relative figures for the Acquisition computed using applicable bases under Rule 1006 of the Listing Manual of the SGX-ST is as follows:

Rule 1006	Bases	Relative figures %
(a)	The net asset value of the assets to be disposed of, compared with the group’s net asset value. This basis is not applicable to an acquisition of assets	not applicable
(b)	The net profits attributable to the assets acquired or disposed of, compared with the group’s net profits.	not applicable
(c)	The aggregate value of the consideration given or received, compared with the issuer’s market capitalization based on the total number of issued shares excluding treasury shares.	14.3
(d)	The number of equity securities issued by the issuer as consideration for an acquisition, compared with the number of equity securities previously in issue.	not applicable

Note: The purchase price of the Property is S\$2,111,110. The Company’s market capitalization as at 28 May 2015 is at S\$14,749,875 based on the weighted average price of the Company’s shares of S\$0.315 per share.

As the relative figure set out under Rule 1006(c) exceeds 5% but does not exceed 20%, the Acquisition constitutes a “Discloseable Transaction” as defined under Chapter 10 of the Listing Manual of the SGX-ST.

7. Interest of the Directors and Substantial shareholders

Save for their interests in the Company, none of the Directors or substantial shareholders of the Company have an interest, direct or indirect, in the Acquisition.

8. Document available for inspection

A copy of the Option will be available for inspection during normal business hours from 9:00 a.m. to 5:30 p.m. at the Company’s registered office at 6 Battery Road #10-01 Singapore 049909 for a period of 3 months from the date of this announcement.

BY ORDER OF THE BOARD

Xu Zhi Bin
Executive Chairman
2 June 2015